Search

Your search keyword '"Fragoso Y"' showing total 99 results

Search Constraints

Start Over You searched for: Author "Fragoso Y" Remove constraint Author: "Fragoso Y"
99 results on '"Fragoso Y"'

Search Results

1. Elevated pulse pressure and cardiovascular risk associated in Spanish population attended in primary care: IBERICAN study

2. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

3. Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study

4. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European MigraineHeadache Alliance

5. Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national cohort

8. Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis

12. Halting disability progression in multiple sclerosis with immunomodulatory injectable treatments: Is it achievable?

13. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod [Meeting Abstract]

14. Odors as triggering and worsening factors for migraine in men

15. Association between multiple sclerosis prevalence and environmental and genetic factors in Latin America and the Caribbean: An ecological study

21. Clinical and therapeutic predictors of relapse and disability outcomes in neuromyelitis optica spectrum disorder

22. The BCTRIMS expanded consensus on treatment of multiple sclerosis. I. The evidences for the use of immunossupressive agents, plasma exchange and autologous hematopoietic stem cell transplantation,Consenso expandido do BCTRIMS para o tratamento da esclerose múltipla. I. As evidências para o uso de imunossupressores, plasmaférese e transplante autólogo de células tronco

23. Aggressive form of multiple sclerosis can be predicted early after disease onset

24. Early clinical predictors of severe MS

25. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

30. The MSBase pregnancy, neonatal outcomes, and women’s health registry

31. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

32. Early clinical markers of aggressive multiple sclerosis

33. Sex effects across the lifespan in women with multiple sclerosis

34. Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype

35. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder

36. Risk of secondary progressive multiple sclerosis: A longitudinal study

37. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

38. Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study.

39. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

40. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.

41. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.

42. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.

43. Family planning considerations in people with multiple sclerosis.

44. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.

45. Comparative effectiveness in multiple sclerosis: A methodological comparison.

46. Confirmed disability progression as a marker of permanent disability in multiple sclerosis.

47. Practical issues concerning the use of Magnetic Resonance Imaging in Multiple Sclerosis in Latin America: Discussion from 16 centres on behalf of the Foro Latam EM Study Group.

48. Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders.

49. The MSBase pregnancy, neonatal outcomes, and women's health registry.

50. Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.

Catalog

Books, media, physical & digital resources